Response to letter to the editor on ‘Mind the gap’

We thank Professor Zalcberg and Michael Wonder for their letter (Semin Oncol [in press]). We are satisfied that our methods [1] support the conclusion that it is better to selectively fund new medicines demonstrating clear clinical benefit and that are cost-effective and affordable---where new cancer medicines are not the sole arbiters of cancer survival differences between countries.

Source: Seminars in Oncology - September 15, 2017 Category: Cancer & Oncology Authors: Scott Metcalfe, Jackie Evans, R. Matthew Strother, George Laking, Tony Wang, Steffan Crausaz Source Type: research